Skin care active substance and skin care product

Abstract

Provided are a skin care active substance and a skin care product. The skin care active substance comprises, in parts by weight, at least two of 0.0001-12 parts of an antioxidant, 0.05-0.4 parts of a moisturizing and firming agent, 0.05-2 parts of a soothing and anti-irritant agent, and 0.1-15 parts of a moisturizing agent, wherein the antioxidant comprises at least one of ergothioneine, coenzyme Q10, a VC derivative, and a VE derivative; the moisturizing and firming agent comprises at least one of hydrolyzed lupine protein and type XVII collagen; the soothing and anti-irritant agent comprises a peony root extract; and the moisturizing agent comprises at least one of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate. By means of designing the described components and their ratios, the synergistically formed active substance improves the skin condition and exhibits high safety.

Description

Skin care actives, skin care products

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority based on Chinese patent application 202410110447.8 filed on January 25, 2024, and all of its contents are incorporated herein by reference. Technical Field

[0003] The present application relates to the technical field of skin care, and in particular to skin care active ingredients and skin care products. Background Art

[0004] In today's society, people not only face the irritation of sunlight, ultraviolet rays, air pollution, and electronic products, but also face various pressures from life and work. Unhealthy lifestyles such as sun damage, excessive skin care, and emotional anxiety can lead to sub-healthy skin barriers, or even damage to the skin barrier.

[0005] Summary of the Invention

[0006] The present application provides a skin care active ingredient and a skin care product to improve skin condition.

[0007] To solve the above technical problems, the first aspect of the present application provides a skin care active, which includes at least two of 0.0001-12 parts by weight of an antioxidant, 0.05-0.4 parts by weight of a moisturizing and firming agent, 0.05-2 parts by weight of a soothing and anti-allergic agent, and 0.1-15 parts by weight of a moisturizer in a weight ratio; wherein the antioxidant includes at least one of ergothioneine, coenzyme Q10, a VC derivative, and a VE derivative; the moisturizing and firming agent includes at least one of hydrolyzed lupin protein and type XVII collagen; the soothing and anti-allergic agent includes peony root extract; and the moisturizer includes at least one of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate.

[0008] In one embodiment, the skin care active comprises, by weight, 0.5-5 parts by weight of ceramide NP and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate; or

[0009] The skin care active ingredients include, by weight, 0.5-5 parts by weight of ceramide NP and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate; or

[0010] The skin care active ingredients include, by weight, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

[0011] In one embodiment, the skin care active ingredient comprises, by weight, at least one of: 0.0001-3 parts by weight of ergothioneine, 0.0001-3 parts by weight of coenzyme Q10, 0.0001-3 parts by weight of VC derivatives, and 0.0001-3 parts by weight of VE derivatives.

[0012] In one embodiment, the skin care active ingredient comprises, by weight, at least one of: 0.05-0.2 parts by weight of hydrolyzed lupin protein and 0.05-0.2 parts by weight of type XVII collagen.

[0013] In one embodiment, the skin care active is composed of the following components in the following weight ratios: 0.0001-3 parts by weight of ergothioneine, 0.05-0.2 parts by weight of hydrolyzed lupin protein, 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.05-2 parts by weight of peony root extract; or,

[0014] The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.0001-3 parts by weight of ergothioneine; or

[0015] The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.05-0.2 parts by weight of hydrolyzed lupin protein; or

[0016] The skin care active ingredient is composed of the following components in the following weight ratios: 0.05-2 parts by weight of peony root extract, 0.05-0.2 parts by weight of hydrolyzed lupin protein, and 0.0001-3 parts by weight of ergothioneine; or,

[0017] The skin care active ingredient is composed of the following components in the following weight ratios: 0.1-10 parts by weight of hydrolyzed sodium hyaluronate or sodium hyaluronate, 0.0001-3 parts by weight of ergothioneine; or

[0018] The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.05-0.2 parts by weight of hydrolyzed lupin protein.

[0019] In one embodiment, in the 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of the hydrolyzed sodium hyaluronate to the sodium hyaluronate is (2.5-4):(1.5-3).

[0020] In order to solve the above technical problems, the second aspect of the present application provides a skin care product, comprising any of the skin care active ingredients described above.

[0021] In one embodiment, the skin care product comprises 0.0501-29.4 parts by weight of the skin care active ingredient and 6-15 parts by weight of a base material.

[0022] In one embodiment, the skin care product consists of the skin care active, the base and deionized water.

[0023] In one embodiment, the base material is composed of the following components in the following weight ratios: 2-6 parts by weight of glycerin, 1.5-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid or acrylate or C10-30 alkyl acrylate crosspolymer, and 1-2 parts by weight of polysorbate 60.

[0024] The beneficial effects of the present application are as follows: Different from the prior art, the present application discloses a skin care active ingredient and a skin care product; the skin care active ingredient comprises, by weight, at least two of an antioxidant (0.0001-12 parts by weight), a moisturizing and firming agent (0.05-0.4 parts by weight), a soothing and anti-allergic agent (0.05-2 parts by weight), and a moisturizer (0.1-15 parts by weight); wherein the antioxidant comprises at least one of ergothioneine, coenzyme Q10, a VC derivative, and a VE derivative; the moisturizing and firming agent comprises at least one of hydrolyzed lupin protein and type XVII collagen; the soothing and anti-allergic agent comprises a peony root extract; and the moisturizer comprises at least one of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate. By designing the above ingredients and their proportions, the synergistically formed active ingredient improves skin condition and is highly safe.

[0025] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.

[0027] FIG1 is a comparison chart of cell proliferation activity test results;

[0028] Figure 2 is a comparison of the relative expression levels of TRPV1 in each group;

[0029] FIG3 is a comparison chart of the TNF-ɑ content test results of each group;

[0030] FIG4 is a comparison chart of the test results of PGE-2 content in each group;

[0031] Figure 5 is a comparison of the epidermal thickness results of each group;

[0032] Figure 6 is a diagram of the histological observation results of each group;

[0033] FIG7 is a graph showing the mean fluorescence intensity of FLG in each group. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and effect of this application clearer and more specific, the following embodiments of the technical solution of this application will be described in detail with reference to the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of this application and are therefore only examples and are not intended to limit the scope of protection of this application.

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" and any variations thereof in the specification and claims of this application and the above-mentioned figure descriptions are intended to cover non-exclusive inclusions.

[0036] In the description of the embodiments of the present application, the technical terms "first" and "second" are used only to distinguish different objects and should not be understood as indicating or implying relative importance or implicitly indicating the quantity, specific order, or primary and secondary relationship of the indicated technical features. In the description of the embodiments of the present application, the term "multiple" refers to more than two (including two), similarly, "multiple groups" refers to more than two (including two), and "multiple pieces" refers to more than two (including two), unless otherwise clearly and specifically defined.

[0037] References herein to "embodiments" mean that a particular feature, structure, or characteristic described in connection with the embodiments may be included in at least one embodiment of the present application. The appearance of this phrase in various places in the specification does not necessarily refer to the same embodiment, nor does it constitute an independent or alternative embodiment that is mutually exclusive of other embodiments. It is understood, both explicitly and implicitly, by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0038] In the description of the embodiments of this application, the term "and / or" is simply a description of the association relationship between associated objects, indicating that three relationships can exist. For example, A and / or B can represent the following three situations: A exists alone, A and B exist simultaneously, and B exists alone. In addition, the character " / " in this document generally indicates that the associated objects are in an "or" relationship.

[0039] Amounts, ratios, and other numerical values ​​are presented herein in a range format. It should be understood that such range format is used for convenience and brevity and should be interpreted flexibly to include not only the values ​​explicitly specified as range limits, but also all individual values ​​or sub-ranges encompassed within the range, as if each value and sub-range were explicitly specified.

[0040] If not otherwise specified, all steps of the present application may be performed sequentially, randomly, or in parallel, preferably sequentially. For example, the method includes steps (a) and (b), indicating that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially, or may include steps (a) and (b) performed simultaneously in parallel. For example, the method may further include step (c), indicating that step (c) may be added to the method in any order, for example, the method may include steps (a), (b), and (c), or may include steps (a), (c), and (b), or may include steps (c), (a), and (b), etc.

[0041] The surface of the skin has a natural skin barrier, which is simply a "protective film". It is like a natural guard that protects human skin, helping the skin resist various stimuli from the external environment, preventing the loss of moisture and nutrients in the skin, and maintaining the skin's hydration and health.

[0042] In today's society, people not only face the irritation of sunlight, ultraviolet rays, air pollution, and electronic products, but also face various pressures from life and work. Unhealthy lifestyles such as sun damage, excessive skin care, and emotional anxiety can lead to sub-healthy or even damaged skin barriers, resulting in sensitive skin.

[0043] In view of this, the present application provides a skin care active ingredient and a skin care product that improves skin condition and is highly safe.

[0044] The present invention provides a skin care active ingredient. The skin care active ingredient includes, by weight, at least two of an antioxidant (0.0001-12 parts by weight), a moisturizing and firming agent (0.05-0.4 parts by weight), a soothing and anti-allergic agent (0.05-2 parts by weight), and a moisturizer (0.1-15 parts by weight); wherein the antioxidant includes at least one of ergothioneine, coenzyme Q10, a VC derivative, and a VE derivative; the moisturizing and firming agent includes at least one of hydrolyzed lupine protein and type XVII collagen; the soothing and anti-allergic agent includes peony root extract; and the moisturizer includes at least one of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate.

[0045] Among them, antioxidants can intelligently target mitochondria and the cell nucleus, providing long-lasting antioxidant effects. For example, ergothioneine is a long-lasting antioxidant that intelligently targets mitochondria and the cell nucleus, exhibiting certain anti-aging effects and improving skin condition.

[0046] The main function of moisturizing and firming agents is to promote collagen production and skin firmness, while also increasing skin moisture content. For example, hydrolyzed lupin protein stimulates collagen synthesis within cells, improving skin elasticity and firmness. It also has moisturizing properties, increasing skin moisture content, improving dryness and roughness, and improving skin condition.

[0047] Soothing and anti-allergic agents achieve soothing and anti-allergic effects through mitochondrial autophagy. For example, peony root extract optimizes cellular energy efficiency through mitochondrial autophagy, achieving soothing and anti-allergic effects, thereby resisting skin aging and improving skin condition.

[0048] Ceramide NP is the main raw material for the brick wall structure of the skin barrier. It also stimulates the synthesis of endogenous sebum components, provides moisturizing and repair for dry and aging skin, and thus improves skin condition.

[0049] The functions of hydrolyzed sodium hyaluronate and sodium hyaluronate are to strengthen the skin barrier, lock in moisture, achieve moisturizing effects, and improve skin condition.

[0050] Improved skin condition is achieved by designing skin care active ingredients to include at least two of the following: an antioxidant, moisturizing and firming agent, a soothing and anti-allergic agent, and a humectant, all of which have skin-improving effects. Specifically, the antioxidant, moisturizing and firming agent, soothing and anti-allergic agent, and humectant each improve skin condition from different perspectives. Combining at least two of these agents improves skin condition from multiple perspectives, allowing the skin care active ingredients to act in diverse pathways, resulting in gentle and effective improvements to skin condition.

[0051] In addition, the weight proportions of the various components of the skin care actives are designed as above, so that the skin care actives can act on the skin to have moisturizing, soothing, repairing, and anti-oxidation effects, and the effects are long-lasting without burdening the skin. It is highly safe, gently and efficiently improves skin condition, effectively protects the skin barrier, and maintains skin health.

[0052] It's important to note that healthy skin refers to skin that is smooth, soft, hydrated, even, firm, elastic, and flawless, based on the normal functioning of its physiological functions. Health is the foundation of beauty, and only healthy skin can achieve beauty. By empowering the skin with "balance, resilience, and self-healing abilities," we can gently and effectively maintain healthy skin.

[0053] Balance: The skin's surface and underlying layers, the stratum corneum and basal layer, each tightly bound together, enable the skin to maintain moisture and prevent water loss. The skin's ability to absorb and retain water, as well as the skin cells' ability to absorb and utilize oxygen, influence the skin's water balance and moisturizing capacity, as well as its metabolism and health, including its ability to heal itself.

[0054] Self-healing ability: The skin's ability to repair itself from damage, trauma, cell aging, etc., as well as the skin cells' ability to absorb and metabolize nutrients, affect the skin's metabolism and repair ability.

[0055] Resistance: The skin's ability to resist external environmental factors, including sunlight, pollutants, ultraviolet rays, bacteria, etc., as well as the skin cells' ability to identify and resist external pathogens and viruses, affect the health and appearance of the skin.

[0056] In this application, ergothioneine, coenzyme Q10, VC derivatives, and VE derivatives correspond to "self-healing power," hydrolyzed lupin protein and type XVII collagen correspond to "self-healing power," ceramide NP corresponds to "resistance," hydrolyzed sodium hyaluronate and sodium hyaluronate correspond to "balancing power," and peony root extract corresponds to "self-healing power." This application designs skin care active ingredients to include at least two of antioxidants, moisturizing and firming agents, soothing and anti-allergic agents, and moisturizers, ensuring that the skin care active ingredients always include "self-healing power" components. This improves the skin's ability to self-repair from damage, trauma, and cell aging, thereby fundamentally repairing the skin and alleviating skin damage. In addition to possessing "self-healing power," skin care active ingredients also possess "resistance" and / or "balancing power" components, further fundamentally improving the skin and promoting skin health.

[0057] From another perspective, based on the framework of "balance, resistance, and self-healing power", the use of a combination of active ingredients that are "human homologous and plant-derived" can gently and efficiently achieve moisturizing, soothing, and repairing effects, promoting the skin to a healthy state. The ceramide NP, sodium hyaluronate, hydrolyzed sodium hyaluronate, type XVII collagen, coenzyme Q10, VC derivatives, and VE derivatives in this application are ingredients that are human homologous, while ergothioneine, hydrolyzed lupine protein, and peony root extract are ingredients that are plant-derived. This application designs skin care active ingredients to include at least two of antioxidants, moisturizing and firming agents, soothing and anti-allergic agents, and moisturizers, so that the skin care active ingredients have both human homologous ingredients and plant-derived ingredients, achieving moisturizing, soothing, and repairing effects efficiently and gently.

[0058] In one embodiment, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises ceramide NPs, hydrolyzed sodium hyaluronate, and sodium hyaluronate, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

[0059] Wherein, 0.1-10 weight parts of hydrolyzed sodium hyaluronate and sodium hyaluronate refer to the total weight parts of hydrolyzed sodium hyaluronate and sodium hyaluronate in the skin care active material is 0.1-10 weight parts. In 0.1-10 weight parts of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is (2.5-4): (1.5-3). Exemplary, in 0.1-10 weight parts of hydrolyzed sodium hyaluronate and sodium hyaluronate, sodium hyaluronate includes sodium hyaluronate with a molecular weight of 220 WDa (ten thousand Daltons), sodium hyaluronate with a molecular weight of 138 WDa (ten thousand Daltons), and sodium hyaluronate with a molecular weight of 36 WDa (ten thousand Daltons), and hydrolyzed sodium hyaluronate includes hydrolyzed sodium hyaluronate with a molecular weight of 3.9 WDa (ten thousand Daltons) and hydrolyzed sodium hyaluronate with a molecular weight of 7-8 KDa (kilo Daltons). 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate have hyaluronic acid of various molecular weights, covering the skin surface to the deep layer of the skin, strengthening the skin barrier function, locking in moisture, and achieving a moisturizing effect. The 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate in the following content are the same and will not be repeated. Exemplarily, in 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate can be 3.5:2.5, 3:2.5, 3:2, 3.5:2, etc.

[0060] In one embodiment, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises ceramide NPs and hydrolyzed sodium hyaluronate, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate.

[0061] In one embodiment, the skin care active comprises 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises hydrolyzed sodium hyaluronate and sodium hyaluronate, the skin care active comprises 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

[0062] In one embodiment, the skin care active comprises at least one of 0.0001-3 parts by weight of ergothioneine, 0.0001-3 parts by weight of coenzyme Q10, 0.0001-3 parts by weight of a VC derivative, and 0.0001-3 parts by weight of a VE derivative. It will be appreciated that when the antioxidant consists of ergothioneine, the skin care active comprises 0.0001-3 parts by weight of ergothioneine.

[0063] In one embodiment, the skin care active comprises 0.05-0.2 parts by weight of hydrolyzed lupin protein and / or 0.05-0.2 parts by weight of XVII collagen. It is understood that when the moisturizing and firming agent is composed of hydrolyzed lupin protein, the skin care active comprises 0.05-0.2 parts by weight of hydrolyzed lupin protein.

[0064] In one embodiment, the skin care active comprises a soothing anti-allergic agent. When the soothing anti-allergic agent is composed of a peony root extract, the skin care active comprises 0.05-2 parts by weight of the peony root extract.

[0065] In one specific embodiment, the skin care active is composed of the following components in the following weight ratio: 0.0001-3 parts by weight of ergothioneine, 0.05-0.2 parts by weight of hydrolyzed lupin protein, 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.05-2 parts by weight of peony root extract.

[0066] In one embodiment, the skin care active is composed of the following components in the following weight ratio: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.0001-3 parts by weight of ergothioneine.

[0067] In one embodiment, the skin care active is composed of the following components in the following weight ratio: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.05-0.2 parts by weight of hydrolyzed lupin protein.

[0068] In one embodiment, the skin care active ingredient is composed of the following components in the following weight ratio: 0.05-2 parts by weight of peony root extract, 0.05-0.2 parts by weight of hydrolyzed lupin protein, and 0.0001-3 parts by weight of ergothioneine.

[0069] In one embodiment, the skin care active is composed of the following components in the following weight ratio: 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.0001-3 parts by weight of ergothioneine.

[0070] In one embodiment, the skin care active is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.05-0.2 parts by weight of hydrolyzed lupin protein.

[0071] It should be noted that when the skin care active includes at least one of ergothioneine, coenzyme Q10, VC derivatives, and VE derivatives, the weight parts of ergothioneine, coenzyme Q10, VC derivatives, and VE derivatives in the skin care active can be 0.0001 weight parts, 0.001 weight parts, 0.01 weight parts, 0.1 weight parts, 1 weight part, 2 weight parts, 3 weight parts, etc., respectively, or a range consisting of any two of the above values, for example, 0.0001-1 weight parts, 0.1-2 weight parts, etc.

[0072] When the skin care active includes at least one of hydrolyzed lupine protein and type XVII collagen, the weight amounts of hydrolyzed lupine protein and type XVII collagen in the skin care active can be 0.05 parts by weight, 0.08 parts by weight, 0.11 parts by weight, 0.14 parts by weight, 0.17 parts by weight, 0.2 parts by weight, etc., respectively, or a range consisting of any two of the above values, for example, 0.05-0.14 parts by weight, 0.08-0.17 parts by weight, etc.

[0073] When the skin care active includes peony root extract, the weight portion of the peony root extract in the skin care active can be 0.05 weight part, 0.08 weight part, 0.11 weight part, 0.14 weight part, 0.17 weight part, 0.2 weight part, 0.6 weight part, 0.8 weight part, 1 weight part, 1.2 weight parts, 1.4 weight parts, 1.6 weight parts, 1.8 weight parts, 2 weight parts, etc., or a range consisting of any two of the above values, for example, 0.05-1 weight part, 0.14-1.4 weight parts, etc.

[0074] When the skin care active includes ceramide NPs, the weight amount of ceramide NPs in the skin care active can be 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, etc., or a range consisting of any two of the above values, such as 0.5-2 parts by weight, 2-4 parts by weight, etc.

[0075] When the skin care active includes hydrolyzed sodium hyaluronate and sodium hyaluronate, the total weight of hydrolyzed sodium hyaluronate and sodium hyaluronate in the skin care active can be 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 10 parts by weight, etc., or a range consisting of any two of the above values, for example, 0.1-5 parts by weight, 3-8 parts by weight, etc.

[0076] When the skin care active includes hydrolyzed sodium hyaluronate, the weight amount of hydrolyzed sodium hyaluronate in the skin care active can be 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 10 parts by weight, etc., or a range consisting of any two of the above values, for example, 0.1-2 parts by weight, 1-7 parts by weight, etc.

[0077] The embodiments of the present application also provide a skin care product, which includes the skin care active ingredients introduced in the above embodiments and has at least the same advantages as the above skin care active ingredients.

[0078] In one embodiment, the skin care product comprises, by weight, 0.0501-29.4 parts of a skin care active and 6-15 parts of a base. The base typically includes a moisturizing ingredient. Optionally, the skin care product comprises, by weight, 0.1001-20.2 parts of the skin care active. The composition and proportions of the skin care active are as described above and are not further described.

[0079] The combination of skin care active ingredients and base materials forms a skin care product that can gently and effectively produce moisturizing, soothing and repairing effects, effectively protecting the skin barrier and maintaining skin health.

[0080] In one embodiment, the skin care product comprises a skin care active ingredient, a base, and deionized water. Optionally, the amount of deionized water to be added is calculated from the total weight of the skin care product being 100 parts by weight minus the sum of the weight of the skin care active ingredient and the weight of the base.

[0081] In one embodiment, the dosage form of the skin care product includes any one of a water solution, an emulsion, a cream, an essence lotion, a facial mask, and a spray. The skin care active ingredient can achieve moisturizing, soothing, and repairing effects in any of these dosage forms. The dosage form is selected based on specific needs; the base ingredients are designed based on the desired dosage form.

[0082] In one embodiment, the base comprises the following components in the following weight ratios: 2-6 parts by weight of glycerin, 1.5-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid, acrylic acid esters, or C10-30 alkyl acrylate crosspolymer, and 1-2 parts by weight of polysorbate 60. This base can be used in a serum emulsion formulation, where polysorbate 60 provides an emulsifying effect and acrylic acid esters provide a thickening effect.

[0083] In one embodiment, the skin care product comprises the following components in the following weight ratios: 0.0001-3 parts by weight of ergothioneine, 0.05-0.2 parts by weight of hydrolyzed lupin protein, 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of sodium hyaluronate and hydrolyzed sodium hyaluronate, 0.05-2 parts by weight of peony root extract, 2-6 parts by weight of glycerin, 1.5-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid or acrylate or C10-30 alkyl acrylate crosspolymer, 1-2 parts by weight of polysorbate 60, and the remaining parts by weight of deionized water. The total weight of the skin care product is 100 parts.

[0084] The skin care actives provided herein have moisturizing, soothing, and repairing effects, and relevant experimental tests and studies have been conducted at the cellular and skin membrane levels. Taking a skin care product composed of the following components in the following weight ratio: 0.1 parts by weight of ergothioneine, 0.1 parts by weight of hydrolyzed lupine protein, 1.5 parts by weight of ceramide NP, 1 part by weight of sodium hyaluronate and hydrolyzed sodium hyaluronate (the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is 3:2), 0.4 parts by weight of peony root extract, 5 parts by weight of glycerin, 2.4 parts by weight of polydimethylsiloxane, 2 parts by weight of squalane, 0.7 parts by weight of C10-30 alkyl acrylate crosspolymer, 1.3 parts by weight of polysorbate 60, and 85.5 parts by weight of deionized water as an example, experimental tests at the cellular and skin membrane levels were conducted.

[0085] 1. Cell proliferation activity assay.

[0086] Experimental steps:

[0087] (1) HSF cells were seeded into 96-well plates, and 100 μL of culture medium containing 8*103 HSF cells was added to each well. The plates were incubated at 37°C for 24 h until the cells adhered to the plate and entered the logarithmic growth phase.

[0088] (2) After 24 hours, the culture medium in step (1) was discarded, and 100 μL of the test solution of different concentrations was added to each well. Three parallel wells were set for each concentration, and the cells were incubated for 24 hours.

[0089] (3) Aspirate the test medium added in step (2), add 90 μL of fresh culture medium and 10 μL of CCK-8 solution (Cell Counting Kit-8 reagent), and incubate for 1 to 4 hours.

[0090] (4) Measure the absorbance at 450 nm using an enzyme-labeled instrument.

[0091] Calculation method: Cell viability*(%)=[A(sample added)-A(blank) / [A(0 sample added)-A(blank)]×100;

[0092] Wherein, A(sample added) represents the absorbance of the wells containing cells, CCK-8 solution, and test solution;

[0093] A (blank) indicates the absorbance of wells with culture medium and CCK-8 solution but no cells;

[0094] A(0 loading) represents the absorbance of the wells containing cells and CCK-8 solution but no test solution;

[0095] Cell viability* indicates cell proliferation activity or cytotoxic activity.

[0096] It should be noted that when adding the culture medium containing CCK-8 to the cells in step (3), several blank wells without cells are added simultaneously to correct the values, which are referred to as A (blank). In step (2), several wells do not contain the test solution, but only the cell culture medium, which are referred to as A (0 addition).

[0097] Experimental results:

[0098] The experimental results are shown in Figure 1, which compares the results of the cell proliferation activity test. Based on Figure 1, the data were fitted to a CV90 of 5.576 mg / mL. Combined with microscopic examination of cell morphology, we selected a viability of 90% or higher as the recommended starting concentration. For efficacy testing on the skin membrane layer, the recommended test concentration is 0.60 mg / mL.

[0099] 2. DPPH free radical scavenging experiment.

[0100] Experimental steps:

[0101] (1) Reagent preparation: Prepare a 150 μM DPPH (i.e., 150 μmol / L DPPH) solution in 80% ethanol.

[0102] (2) Sample addition: Add 20 μL of sample to each well, then add 180 μL of DPPH solution, and react at room temperature in the dark for 30 minutes.

[0103] (3) Detection: The absorbance at 517 nm was measured using an enzyme-labeled instrument, and the inhibition rate was calculated.

[0104] Calculation method: inhibition rate % = (1-A1 / A0) × 100%;

[0105] Wherein, A0 represents the absorbance value of the blank group at 517 nm; A1 represents the absorbance value of the sample group at 517 nm.

[0106] It should be noted that sample is the skin care product of the present application. Blank group refers to that sample is not added in the hole. In DPPH free radical scavenging experiment, the skin care product provided in the embodiment of the present application, thioneine, hydrolysis lupin protein, ceramide NP, 5 heavy hyaluronic acids (including the sodium hyaluronate with a molecular weight of 220WDa, the sodium hyaluronate with a molecular weight of 138WDa, the sodium hyaluronate with a molecular weight of 36WDa, the hydrolysis sodium hyaluronate with a molecular weight of 3.9WDa, the hydrolysis sodium hyaluronate with a molecular weight of 7-8KDa), and peony root extract are respectively used as the sample in step (2), experimented successively. The concentration of ergothioneine is the same as the concentration of ergothioneine in the skin care active of the skin care product; the concentration of hydrolyzed lupin protein is the same as the concentration of hydrolyzed lupin protein in the skin care active of the skin care product; the concentration of ceramide NP is the same as the concentration of ceramide NP in the skin care active of the skin care product; the concentration of quintuple hyaluronic acid is the same as the concentration of quintuple hyaluronic acid in the skin care active of the skin care product and has the same composition as the quintuple hyaluronic acid in the skin care active; and the concentration of peony root extract is the same as the concentration of peony root extract in the skin care active of the skin care product.

[0107] Experimental results:

[0108] The experimental results are shown in Table 1 below. The skin care active provided in the embodiment of the present application can significantly inhibit DPPH free radicals with a scavenging rate of 49.5%, and has significant antioxidant effect. The free radical scavenging rate of the skin care active provided in the embodiment of the present application is higher than that of each single component in the skin care active, reflecting the synergistic efficiency of the composition. It should be noted that the concentration of ergothioneine in the skin care active at a concentration of 10% is equivalent to 0.1%, the concentration of hydrolyzed lupin protein in the skin care active at a concentration of 10% is equivalent to 0.01%, the concentration of ceramide NP in the skin care active at a concentration of 10% is equivalent to 0.1%, the concentration of 5-fold hyaluronic acid in the skin care active at a concentration of 10% is equivalent to 0.1%, and the concentration of peony root extract in the skin care active at a concentration of 10% is equivalent to 0.1%.

[0109] Table 1 DPPH test results of skin care actives and active monomers of skin care actives

[0110] 3. Skin model: TRPV1 test.

[0111] Experimental steps:

[0112] (1) Preparation of skin model. Add pre-warmed maintenance culture medium to a 12-well culture plate (2 mL / well), transfer the skin model to the medium containing the maintenance culture medium, and culture in an incubator overnight.

[0113] (2) Sample application: Take 50 μL of the test sample and evenly apply it to the surface of the epidermal model. Refer to Table 2 for test groups and exposure conditions. Set up three parallel groups for each test group. After the specified exposure time, rinse the sample thoroughly with DPBS until no residue is left.

[0114] (3) Modeling: DPBS buffer solution was used as the culture medium. Except for the control group (NC), the other groups were set at 0.2 mW / cm 2 Modeling was performed by irradiating with UVB for 5 minutes. After UVB irradiation, the cells were replaced with maintenance medium and returned to the incubator for 30 minutes.

[0115] Table 2 TRPV1 test grouping and sample addition table

[0116] (4) Remove the epidermal tissue from the skin model with a punch, transfer it to a 1.5 mL EP centrifuge tube, add 1 mL Trizol, mix well, and let it stand at room temperature for 5 minutes. Add 0.2 mL chloroform, shake for 30 seconds, and let it stand for 2 minutes. Centrifuge at 4°C, 14,000 g for 15 minutes, and remove the supernatant. Add an equal volume of isopropanol, gently mix the liquid in the tube, and let it stand for 10 minutes. Centrifuge at 4°C, 14,000 g for 10 minutes, and discard the supernatant. Add 1 mL 75% ethanol and gently wash the precipitate. Centrifuge at 4°C, 7,500 g for 5 minutes, and discard the supernatant. Let it dry and add an appropriate amount of DEPC H2O to dissolve it.

[0117] (5) Primer design. See Table 3 for details.

[0118] Table 3 Primer design

[0119] (6) Reverse transcription to synthesize cDNA (total system is 20 μL).

[0120] (7)qPCR.

[0121] qPCR system: 20 μL, cDNA (1:20), 5.0 μL, upstream primer, 0.5 μL, downstream primer, 0.5 μL, 2x SYBR Green qPCR Super Mix, 10 μL, dH2O, 8.2 μL.

[0122] Experimental results:

[0123] The experimental results are shown in Table 4 and Figure 2. Figure 2 is a comparison of the relative expression levels of TRPV1 in each group.

[0124] Table 4 Relative expression of TRPV1 in each group (Mean±SD)

[0125] As shown in Table 4 and Figure 2, under UVB stimulation, the relative expression of TRPV1 in the model group increased significantly compared to the control group, increasing by 0.35 (p < 0.05); the relative expression of TRPV1 in the positive group decreased significantly compared to the model group, decreasing by 0.29 (p < 0.05), indicating successful modeling. Compared with the model group, the relative expression of TRPV1 in the sample group decreased significantly, decreasing by 0.52 (p < 0.05), indicating that the skin care product of the present application has a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0126] It should be noted that in Table 4 and Figure 2, * indicates that the difference is statistically significant compared with the model group (P < 0.05); # indicates that the difference is statistically significant compared with the control group (P < 0.05).

[0127] 4. Skin model: TNF-ɑ, PGE-2, tissue morphology test.

[0128] Experimental Materials:

[0129] (1) Detection kit: Episkin in vitro artificial skin model detection kit, batch number: 23ER060515S1.

[0130] (2) Culture conditions: 37°C, 5% CO2, relative humidity 95%.

[0131] (3) Culture medium: skin model maintenance culture medium (Lot: 23-MAIN-0512) and test culture medium (Lot: 23-ASSAY-0512).

[0132] (4) Tissue fixative: 4% neutral paraformaldehyde solution.

[0133] (5) Human TNF-α ELISA kit, Lot: H221109-103a.

[0134] (6) PGE-2 ELISA kit, Lot: 0674976.

[0135] (7) Sodium dodecyl sulfate (SDS): CAS: 151-21-3, LOT: WXBD6396V.

[0136] Experimental steps:

[0137] (1) Skin model preparation: Add pre-warmed maintenance culture medium into a 12-well culture plate (2 mL / well), transfer the skin model to the plate containing the maintenance culture medium, and culture in an incubator overnight.

[0138] (2) Sample application: Take 10 μL of the test sample and evenly apply it to the surface of the epidermal model. The experimental groups and exposure conditions are shown in Table 5. Each experimental group has three parallels. After the specified exposure time, the sample is thoroughly rinsed with DPBS until no residue is left. Then, it is placed in fresh maintenance medium for further incubation or exposure to the test substance. It should be noted that TA in Table 5 represents sample.

[0139] Table 5 Grouping sample addition table

[0140] (3) Remove the epidermal tissue from the skin model using a punch and transfer it to a 2 mL EP centrifuge tube. Add 2 mL of neutral paraformaldehyde solution to each tube and fix it at room temperature for at least 24 h. After conventional embedding, sectioning, and HE staining, observe the morphology under a microscope.

[0141] (4) The culture medium of each well model was collected and stored at -80°C. The TNF-α content and PGE-2 content were determined using an ELISA kit.

[0142] Experimental results:

[0143] (1)TNF-ɑ.

[0144] The results of TNF-ɑ content are shown in Table 6 and Figure 3. Figure 3 is a comparison chart of the test results of TNF-ɑ content in each group.

[0145] Table 6 TNF-ɑ content results

[0146] In Table 6 and Figure 3, * indicates that the difference compared with the model group is statistically significant (P < 0.05); # indicates that the difference compared with the control group is statistically significant (P < 0.05). According to Table 6 and Figure 3, when the epidermal model was damaged by SDS, the TNF-α content of the model group was significantly increased compared with the control group (p < 0.05), indicating that the model was successful; compared with the model group, the TNF-α content of the positive group was significantly reduced, by 44.00% (p < 0.05). Compared with the model group, the TNF-α content of the sample group was significantly reduced, by 26.19% (p < 0.05), indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0147] (2) PGE-2.

[0148] The results of PGE-2 content are shown in Table 7 and Figure 4. Figure 4 is a comparison chart of the test results of PGE-2 content in each group.

[0149] Table 7 PGE-2 content results

[0150] In Table 7 and Figure 4, * indicates that the difference is statistically significant compared with the model group (P < 0.05); # indicates that the difference is statistically significant compared with the control group (P < 0.05). According to Table 7 and Figure 4, the epidermal model was damaged by SDS. Compared with the control group, the PGE-2 content in the model group increased significantly (p < 0.05), indicating that the modeling was successful; compared with the model group, the PGE-2 content in the positive group decreased significantly, decreasing by 27.05% (p < 0.05). Compared with the model group, the PGE-2 content in the sample group decreased significantly, decreasing by 27.02% (p < 0.05), indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0151] (3) Tissue morphology and epidermal thickness.

[0152] The results of histological analysis are shown in Table 8 and Figures 5 and 6. Figure 5 is a comparison of the epidermal thickness results of each group. Figure 6 is a diagram of the histological observation results of each group (under a microscope at 400×).

[0153] Table 8 Histological analysis results

[0154] In Table 8 and Figure 5, * indicates that the difference is statistically significant compared with the model group (P < 0.05); # indicates that the difference is statistically significant compared with the control group (P < 0.05). According to Table 8 and Figures 5 and 6, the epidermal model is significantly thinner and the cell layer is reduced in the model group compared with the control group under the action of SDS damage, and the SDS modeling is effective (p < 0.05). After SDS damage, the sample (i.e., the skin care product of the present application) was applied. Compared with the model group, the epidermal thickness of the sample group was significantly increased, 369.80μm (p < 0.05), indicating that the skin care product of the present application has a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0155] The results of tissue morphology test showed that compared with the control group, the epidermis of the model group epidermis model was thinner, the living cell layer was damaged, the number of living cell layers decreased, and vacuoles appeared, indicating that the SDS stimulation modeling conditions were effective. Compared with the model group, the four-layer structure of the positive group model had clear boundaries, the cells in the cell layer were compactly arranged, and the basal layer was intact, indicating that the positive control test was effective. The epidermal model structure of the sample control group was intact, indicating that the sample itself had no obvious stimulating effect on the epidermal model. Compared with the model group, the tissue morphology of the sample group model was significantly improved, the epidermal model structure was intact, the boundaries were clear, and the cells in the cell layer were compactly arranged, indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after stimulation and damage.

[0156] 5. Skin model: FLG (filament aggregate protein) test.

[0157] Experimental groups:

[0158] Table 9 FLG test experiment grouping

[0159] Experimental reagents: Anti-Filaggrin antibody: Abcam-ab81468.

[0160] Experimental steps:

[0161] (1) Pre-incubation of the whole skin model.

[0162] (a) After receiving the model, first preheat the accompanying culture medium.

[0163] (b) Add preheated culture medium to the included blue deep-well plate at a volume of 8.5 mL per well. Remove the model from the test kit using tweezers, remove any remaining agarose gel culture medium, and immediately transfer it to the pre-filled blue deep-well plate. Ensure that each skin model fits snugly into the well, with the base membrane of each skin model in contact with the liquid surface, ensuring that no air bubbles are trapped between the model and the culture medium.

[0164] (c) Place the plate in an incubator at 37°C, 5% CO2 overnight until use.

[0165] (2) Raw material processing.

[0166] (a) Prepare a certain volume of culture medium containing the active substance according to the concentration.

[0167] (b) Remove the 6-well plate from the incubator, remove the culture medium from the bottom of the model using a pipette, and add 8.5 mL / well of fresh culture medium containing the active ingredient prepared in step (a). After the medium is replaced, ensure that the base membrane of each skin model is in contact with the liquid surface. Return the plate to the incubator and incubate at 37°C, 5% CO2 for 48 hours.

[0168] (3) Collection of skin model samples.

[0169] After the model incubation is complete (i.e., after step (2)), the model is carefully removed from the well plate with tweezers, the skin tissue is punched out with a punch, and the tissue is cut with a sharp blade. The tissue used for immunofluorescence experiments is fixed in OCT frozen section embedding medium. During the fixation process, the bubbles in the OCT gel must be removed. The tissue is then quickly placed in liquid nitrogen, labeled with groups, and stored at -80°C.

[0170] (4) Tissue immunofluorescence.

[0171] Experimental process:

[0172] Allow frozen sections to dry at room temperature for 15 minutes. Use an immunohistochemistry pen to circle the tissue to be stained and soak in PBS for 10 minutes to remove the OCT cryosection embedding medium. Block sections with PBS containing 10% serum at room temperature. Apply various concentrations of primary antibody to the sections and incubate overnight at 4°C. Rinse sections three times with PBS for 10 minutes each. Add various concentrations of secondary antibody and incubate at 37°C for 1-2 hours. Rinse sections three times with PBS for 10 minutes each. Finally, mount the sections and observe the results under a fluorescence microscope and photograph.

[0173] Experimental results:

[0174] The average fluorescence intensity of FLG is shown in Table 10 and Figure 7. Figure 7 is a graph showing the average fluorescence intensity of FLG in each group.

[0175] Table 10 FLG mean fluorescence intensity (Mean±SD)

[0176] As shown in Table 10 and Figure 7, after 48 hours of exposure to T-Skin™ (a skin model) at a concentration of 0.6 mg / mL, the skincare product of this application exhibited significant fluorescence intensity for FLG (filaggrin). The relative fluorescence intensity of FLG accounted for 184.09%, an increase of 84.09% compared to the negative control group, demonstrating that the skincare product of this application exhibits significant moisturizing and repairing properties.

[0177] Testing at the cellular and skin model levels, including DPPH, TRPV1, TNF-ɑ, PGE-2, tissue morphology, and FLG, confirmed that the skincare actives in this application effectively promote soothing, repairing, and moisturizing effects. The DPPH free radical scavenging rate of the skincare actives was higher than that of each individual component, demonstrating the synergistic efficiency of the combination.

[0178] Experimental studies were conducted on the components and addition amounts of the skin care actives provided in the present application. The differences between the embodiments are as follows: the components and addition amounts of the skin care actives are specifically shown in Table 11. The base materials used in the embodiments are the same, specifically: 4 parts by weight of glycerin, 2 parts by weight of polydimethylsiloxane, 1 part by weight of squalane, 1 part by weight of acrylates, 2 parts by weight of polysorbate 60, and the remaining parts by weight are deionized water, with a total weight of 100 parts.

[0179] The proportions of sodium hyaluronate and hydrolyzed sodium hyaluronate in each embodiment in Table 11 are the total proportions by weight, and the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is 3:2.

[0180] Table 11 Test parameters of various embodiments

[0181] As demonstrated in Examples 1 to 15 above, the skincare actives provided in these examples possess moisturizing, soothing, and repairing properties. The specific testing methods for the cell proliferation activity enhancement rates in each example in Table 8 can be found in the descriptions of the aforementioned examples and are omitted here. The testing methods for hyaluronidase inhibition activity and stratum corneum water content enhancement are as follows.

[0182] Experimental steps for hyaluronidase inhibition activity:

[0183] (1) Add 0.1 mL of CaCl solution (2.5 mol / L) to tubes A, B, C, and D, respectively.

[0184] (2) Add 0.5 mL of hyaluronidase solution (1250 U / mL) to tubes A and C.

[0185] (3) Replace the contents of tubes B and D with an equal amount of acetate buffer solution (pH = 5.6; a mixture of 0.2 mol / L sodium acetate and 0.2 mol / L acetic acid, 9.5:1) and keep them warm at 37°C for 20 min.

[0186] (4) Then add 0.5 mL of sample solution to tubes C and D, replace it with acetate buffer solution in tubes A and B, and keep it at 37°C for 20 min.

[0187] (5) Add 0.5 mL of sodium hyaluronate solution (0.5 mg / mL) to each tube, keep it at 37°C for 30 min, let it stand at room temperature for 5 min, and then place it in an 80°C water bath for 20 min.

[0188] (6) After taking out, add 0.1 mL of NaOH solution (0.4 mol / L) and 0.5 mL of acetylacetone solution to each tube, boil in water for 15 minutes, and then quickly ice-bathe for 5 minutes.

[0189] (7) Then add 1 mL of color developer and let it stand for 20 minutes for color reaction.

[0190] (8) The absorbance was measured at a wavelength of 547 nm, and the hyaluronidase inhibition rate was calculated according to the formula.

[0191] Experimental steps for stratum corneum water content:

[0192] 1. Experimental consumables.

[0193] (1) Delfin moisture meter.

[0194] (2) Any sample of Examples 1-15 provided in this application.

[0195] 2. Test site

[0196] Inside the arm, 3*3cm 2 area.

[0197] 3. Test sample dosage

[0198] 2mg / cm 2 .

[0199] 4. Test steps

[0200] 1) For each implementation case, 5 people were selected. After determining the test area, a moisture meter was used to test the initial stratum corneum moisture content at T0, which was recorded as W0.

[0201] 2) After applying the sample, use a moisture meter to test the water content of the stratum corneum 30 minutes later, which is recorded as W1;

[0202] 3) The change rate of stratum corneum water content is: (W1-W0) / W0*%, and finally the average change rate of stratum corneum water content of 5 people is calculated.

[0203] The above description is only an implementation method of the present application and does not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the description and drawings of this application, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A skin care active ingredient, wherein, the skin care active ingredient comprises at least two of 0.0001 - 12 parts by weight of an antioxidant, 0.05 - 0.4 parts by weight of a moisturizing and firming agent, 0.05 - 2 parts by weight of a soothing and anti-allergic agent, and 0.1 - 15 parts by weight of a humectant according to a weight ratio; wherein, the antioxidant comprises at least one of ergothioneine, coenzyme Q10, VC derivative, and VE derivative; the moisturizing and firming agent comprises at least one of hydrolyzed lupetide protein and type XVII collagen; the soothing and anti-allergic agent comprises peony root extract; and the humectant comprises at least one of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate.

2. The skin care active substance according to claim 1, wherein, The skin care active ingredient comprises according to a weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate, and sodium hyaluronate; or, The skin care active ingredient comprises according to a weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate; or, The skin care active ingredient comprises according to a weight ratio: 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

3. The skin care active substance according to claim 1, wherein, The skin care active ingredient comprises at least one of 0.0001 - 3 parts by weight of ergothioneine, 0.0001 - 3 parts by weight of coenzyme Q10, 0.0001 - 3 parts by weight of VC derivative, and 0.0001 - 3 parts by weight of VE derivative according to a weight ratio.

4. The skin care active substance according to claim 1, wherein, The skin care active ingredient comprises at least one of 0.05 - 0.2 parts by weight of hydrolyzed lupetide protein and 0.05 - 0.2 parts by weight of type XVII collagen according to a weight ratio.

5. The skin care active substance according to claim 1, wherein, The skin care active ingredient is composed of components with the following weight ratios: 0.0001 - 3 parts by weight of ergothioneine, 0.05 - 0.2 parts by weight of hydrolyzed lupetide protein, 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract; or, The skin care active ingredient is composed of components with the following weight ratios: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.0001 - 3 parts by weight of ergothioneine; or, The skin care active ingredient is composed of components with the following weight ratios: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract, 0.05 - 0.2 parts by weight of hydrolyzed lupetide protein; or, The skin care active ingredient is composed of components with the following weight ratios: 0.05 - 2 parts by weight of peony root extract, 0.05 - 0.2 parts by weight of hydrolyzed lupetide protein, 0.0001 - 3 parts by weight of ergothioneine; or, The skin care active ingredient is composed of components with the following weight ratios: 0.1 - 10 parts by weight of hydrolyzed sodium hyaluronate or sodium hyaluronate, 0.0001 - 3 parts by weight of ergothioneine; or, The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, and 0.05-0.2 parts by weight of hydrolyzed lupetide protein.

6. The skin care active substance according to claim 2 or 5, wherein, Among the 0.1-10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, the weight ratio of the sodium hyaluronate hydrolyzate to the sodium hyaluronate is (2.5-4):(1.5-3).

7. A skin care product, wherein, It includes the skin care active ingredient according to any one of claims 1 to 6.

8. The skin care product according to claim 7, wherein, The skin care product includes 0.0501-29.4 parts by weight of the skin care active ingredient and 6-15 parts by weight of the base material according to the weight ratio.

9. The skin care product according to claim 8, wherein, The skin care product is composed of the skin care active ingredient, the base material and deionized water.

10. The skin care product according to claim 8 or 9, wherein, The base material is composed of the following components in the following weight ratios: 2-6 parts by weight of glycerol, 1.5-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 part by weight of acrylate or acrylate or C10-30 alkanol acrylate cross-linked polymer, 1-2 parts by weight of polysorbate-60.

Images